Survodutide

People run it for fat loss — strong appetite suppression and the same drop in “food noise” the rest of the GLP-1 class is known for, with weight loss landing between the single-receptor drugs and the triple agonist. The quieter reason it gets attention is the liver: it’s studied specifically for MASH (metabolic dysfunction-associated steatohepatitis, the inflammatory end of fatty-liver disease), where it cleared the disease without worsening scarring in a majority of trial patients at the higher dose.

It sits one rung down the receptor ladder from retatrutide: where the triple agonist adds glucagon on top of GLP-1 and GIP, survodutide pairs glucagon with GLP-1 and skips GIP. That glucagon arm is the whole identity. GLP-1 kills appetite; glucagon raises energy expenditure and, more interestingly, pushes the liver to burn its own stored fat. That’s why the standout trial result here isn’t a weight number — it’s that 62% of people on the 4.8 mg dose had their MASH resolve without fibrosis getting worse, versus 14% on placebo. For a community that’s spent years worrying about liver fat from cycles and hard living, that’s the headline.

A dual agonist of the GLP-1 and glucagon receptors. The GLP-1 arm drives appetite suppression and glucose handling, as in the rest of the class. The glucagon arm is the differentiator: glucagon-receptor activation raises energy expenditure and directly mobilizes fat from the liver, which is the mechanistic basis for the MASH and liver-fat results. That added glucagon load is also why dosing it too fast is rough — the same arm that burns liver fat raises heart rate and nausea, and titration is the whole game.

Gastrointestinal effects dominate, as with the whole class — nausea, vomiting, diarrhea, constipation, decreased appetite — and they’re the main reason people drop out when titration is rushed. The glucagon arm adds a modest heart-rate bump, the same signature retatrutide carries. In the trials the GI effects were mostly mild-to-moderate and tied to the escalation phase; notably, the obesity trial reported no pancreatitis or hepatic-injury signal. As with rapid weight loss generally, muscle loss is the off-target worry, so protein and resistance training are the usual community guardrails. Everything here is from supervised trials — outside that setting, sourcing is unregulated, so insist on a certificate of analysis.

Like the other GLP-1-class fat-loss drugs, it’s run standalone — there’s no community peptide-stacking protocol for it, and pairing two incretin drugs is not something people do. When people talk about “stacking” around it they mean the support scaffolding: high protein and resistance training to protect muscle, plus electrolytes and micronutrients to ride out the GI phase. The work is in diet and training alongside it, not in adding another vial.